Creatine for Depression

What the Research Shows

A 2026 systematic review in the Canadian Journal of Psychiatry evaluated five randomized controlled trials on creatine monohydrate for mood disorders. The review analyzed six published articles covering 238 total participants. Across all five trials, 126 participants received creatine and 112 received an inactive placebo. The mean participant age was 36 years. Only 26 percent of the participants were male. Four trials evaluated patients with major depressive disorder, while one evaluated bipolar depression. The trials were conducted across South Korea, the United States, Brazil, Israel, and India.

Daily doses across the trials ranged from 2 to 10 grams of creatine monohydrate. Treatment periods lasted between 4 and 8 weeks. Every trial administered creatine as an add-on therapy alongside an existing antidepressant or psychotherapy. None of the studies tested creatine as a standalone intervention. Most trials evaluated doses of 5 grams per day or less. The review authors noted that this daily intake might be too low to saturate brain tissue effectively. Human brain tissue takes longer to accumulate creatine than muscle tissue does.

The study designs varied considerably. Because of this substantial heterogeneity, the review authors could not perform a statistical meta-analysis. Study quality was split. Two trials had a low risk of bias, while three had some methodological concerns regarding randomization procedures and missing participant data. The review concluded that creatine shows promise for augmenting adult major depressive disorder treatments, though larger double-blind trials remain necessary before clinicians can recommend it as standard practice.

The Individual Trial Results

The five clinical trials on creatine for depression produced mixed findings. Two trials showed clear symptom reductions, while three found no benefit over placebo. The positive trials observed measurable benefits when adding creatine to standard treatments. Lyoo and colleagues evaluated 52 participants with major depressive disorder who took creatine or placebo alongside the antidepressant escitalopram. At 8 weeks, the creatine group showed greater improvement on the Hamilton Depression Rating Scale. The effect size was large, reaching Cohen's d = 1.13. In addition, the remission rate was 52 percent in the creatine group compared to 25.9 percent in the placebo group. A second positive trial by Sherpa and colleagues evaluated 100 participants combining creatine or placebo with cognitive behavioral therapy. Results favored the supplement. Participants taking creatine achieved a lower depression score of 5.8 on the Patient Health Questionnaire-9, compared to 11.9 in the placebo group.

Other trials failed to find a measurable benefit. Nemets and Levine studied 18 participants with treatment-resistant major depressive disorder. They found no significant treatment effect on depression rating scores. Kondo and colleagues examined 33 adolescent females with selective serotonin reuptake inhibitor-resistant depression. Their study found no significant difference compared to placebo. However, magnetic resonance spectroscopy revealed that brain phosphocreatine levels correlated inversely with depression severity. Higher brain energy stores matched lower symptom scores. In a trial by Toniolo and colleagues on 27 participants with bipolar depression, creatine augmentation produced no significant difference over placebo.

Trial characteristics differed substantially across these five studies. Across the pooled literature, daily doses ranged between 2 and 10 grams for 4 to 8 weeks. Study quality varied. Two studies demonstrated a low risk of bias, while three presented some concerns regarding missing data or randomization procedures.

Creatine as an Adjunct Compared to Standard Care

Creatine monohydrate is an experimental adjunct rather than a standalone alternative to conventional depression care. Standard psychiatric care relies on interventions with decades of randomized trial evidence. By contrast, creatine research in psychiatry consists of five small trials with mixed results. The table below outlines the differences between standard care and adjunctive creatine supplementation.

When should a person consider adjunctive creatine? Only after establishing an active treatment plan with a medical doctor or licensed therapist. If an individual has residual symptoms despite optimized medication, their prescriber may review the adjunctive literature. Creatine should never be started during an untreated depressive episode without clinical oversight.

Safety and Who Should Be Cautious

Creatine monohydrate was generally well-tolerated in the depression trials, but specific clinical groups face meaningful safety considerations. Reported adverse events in the clinical trials were mild. Participants primarily reported gastrointestinal distress, nausea, and headache. Serum creatinine levels remained within normal ranges. This showed no evidence of kidney harm during these 4 to 8 week trials. For the general population, the International Society of Sports Nutrition confirms that standard creatine supplementation has an extensive safety profile when taken at recommended dosages.

Certain patient groups require strict caution. In the bipolar depression trial by Toniolo and colleagues, 2 of 17 participants taking creatine developed hypomania or mania. The review authors noted this signal as an adverse outcome that warrants careful investigation in bipolar populations. Anyone with bipolar disorder or a personal history of mania should consult a psychiatrist before taking creatine. In addition, individuals with pre-existing kidney disease must avoid creatine without medical clearance. Safety has not been established for women who are pregnant or breastfeeding.

Physical energy and mood are closely intertwined. If your low mood coincides with physical fatigue around your menstrual cycle, read our guide on fatigue before your period to evaluate cyclic hormonal shifts. Sleep disruptions also impair daily energy and resilience. Our guide on cortisol and sleep explains how adrenal rhythms and nighttime rest influence daily recovery.

Creatine Is Not a Substitute for Medical Treatment

Creatine is not an alternative to professional mental health care or prescribed psychiatric medications. Every published trial evaluated creatine solely as an add-on therapy alongside ongoing medical care. No clinical trial has tested creatine as a standalone treatment for depression. Stopping an antidepressant to take a supplement is dangerous. Doing so can cause severe withdrawal reactions, acute symptom rebound, and increased risk of self-harm.

Depression is a complex medical condition. It involves neural circuitry, psychological stress, inflammatory markers, and life circumstances. A single metabolic supplement cannot address all of these interacting factors. If you experience persistent sadness, loss of interest, or severe fatigue, talk to a qualified clinician. A doctor can order appropriate blood tests, rule out underlying medical conditions, and recommend evidence-based therapies. Nutritional adjuncts should only be explored under professional supervision.

Who This Is Not For

Creatine for depression is not appropriate for individuals with bipolar disorder, unmonitored kidney disease, or anyone experiencing an acute mental health crisis. Because 2 of 17 participants with bipolar depression developed mania during clinical testing, the risk of mood destabilization is real. Anyone with a personal or family history of hypomania or mania should avoid creatine unless their psychiatrist explicitly directs its use.

People seeking a replacement for their psychiatric medications should also look elsewhere. Creatine has zero evidence as a monotherapy. What would change our stance on creatine for depression? We would reconsider our evaluation if large, multi-center randomized controlled trials demonstrate consistent symptom reductions across diverse patient cohorts. Three of five trials to date showed no benefit over placebo. Future research must also determine whether daily doses above 5 grams produce better brain saturation and clearer clinical outcomes. Until that evidence exists, creatine remains an experimental add-on rather than a proven depression therapy.

Next Steps and What to Discuss with a Clinician

If you want to explore creatine for depression, schedule an appointment with your doctor before buying a supplement. Talk with your prescriber first. Bring the published research to your visit. Your clinician can evaluate potential drug interactions and monitor your mental response. If your doctor approves an adjunctive trial, choose pure creatine monohydrate without proprietary additives. Regular clinical checkups ensure that your digestive tolerance and mood remain stable over several weeks.

Evaluating your broader physical health often reveals overlooked contributors to low energy. Thyroid function, iron status, and glucose regulation all influence brain metabolism. Complete our free health assessment to evaluate your metabolic, hormonal, and sleep patterns before discussing creatine for depression with your healthcare provider.